{"id":"docetaxel-oxaliplatin-s1","safety":{"commonSideEffects":[{"rate":"40–60","effect":"Neutropenia"},{"rate":"30–50","effect":"Anemia"},{"rate":"20–40","effect":"Thrombocytopenia"},{"rate":"30–50","effect":"Nausea/vomiting"},{"rate":"20–40","effect":"Diarrhea"},{"rate":"15–30","effect":"Peripheral neuropathy"},{"rate":"40–60","effect":"Fatigue"},{"rate":"10–25","effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL414804","moleculeType":"Small molecule","molecularWeight":"395.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Docetaxel stabilizes microtubules to prevent cell division, oxaliplatin creates DNA crosslinks to prevent replication, and S-1 (tegafur/gimeracil/oteracil) inhibits thymidylate synthase and incorporates into DNA/RNA. The triple combination exploits synergistic cytotoxic effects across different cell-cycle phases and molecular targets, commonly used in gastric and esophageal cancers.","oneSentence":"This combination regimen uses three chemotherapy agents—docetaxel (microtubule stabilizer), oxaliplatin (platinum crosslinker), and S-1 (fluoropyrimidine)—to attack cancer cells through multiple mechanisms simultaneously.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:56.149Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic gastric cancer"},{"name":"Esophageal cancer"}]},"trialDetails":[{"nctId":"NCT07366528","phase":"PHASE3","title":"Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-12-15","conditions":"Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer","enrollment":387},{"nctId":"NCT07098104","phase":"","title":"A Benefit Population Atlas of nICT Versus nCT for LAGC","status":"COMPLETED","sponsor":"Cheng Chen","startDate":"2019-11-01","conditions":"Gastric Cancer","enrollment":291},{"nctId":"NCT06732856","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-04-04","conditions":"Stomach Neoplasm, Gastric (Stomach) Cancer","enrollment":57},{"nctId":"NCT06440811","phase":"","title":"Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2021-01-01","conditions":"Immune-related Adverse Event, Chemotherapeutic Toxicity, Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":120},{"nctId":"NCT06914687","phase":"PHASE2","title":"Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-03-30","conditions":"Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis","enrollment":30},{"nctId":"NCT06760858","phase":"","title":"A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2024-12-01","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":122},{"nctId":"NCT06682182","phase":"","title":"Tislelizumab Combined with SOX and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Metastasis: a Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2024-12-01","conditions":"Gastric Cancer with Peritoneal Metastasis","enrollment":74},{"nctId":"NCT02969122","phase":"NA","title":"Treatment Strategy for Stage IV Gastric Cancer with Positive Peritoneal Cytology As the Only Non-curable Factor","status":"TERMINATED","sponsor":"Peking University","startDate":"2016-11","conditions":"Stomach Neoplasm","enrollment":59},{"nctId":"NCT06475417","phase":"PHASE2","title":"Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-05-24","conditions":"Gastric Cancer","enrollment":42},{"nctId":"NCT05184803","phase":"PHASE2","title":"A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2022-03-23","conditions":"Stomach Neoplasm","enrollment":63},{"nctId":"NCT06235164","phase":"","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2019-01-01","conditions":"Locally Advanced Gastric Cancer","enrollment":585},{"nctId":"NCT04221555","phase":"PHASE2","title":"Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2020-05-13","conditions":"Resectable Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":68},{"nctId":"NCT03607656","phase":"PHASE2, PHASE3","title":"The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer","status":"COMPLETED","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2018-06-08","conditions":"Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC","enrollment":270},{"nctId":"NCT01515748","phase":"PHASE3","title":"Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-12-30","conditions":"Gastric Cancer","enrollment":530},{"nctId":"NCT04999332","phase":"PHASE2","title":"Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2021-12-10","conditions":"Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy","enrollment":58},{"nctId":"NCT04819971","phase":"PHASE2","title":"Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2021-12-01","conditions":"Stomach Cancer","enrollment":67},{"nctId":"NCT05648487","phase":"PHASE2","title":"HIPEC Combined With Sintilimab for Gastric Cancer With Peritoneal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2023-01-01","conditions":"Gastric Cancer","enrollment":46},{"nctId":"NCT02725424","phase":"PHASE2","title":"Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2015-08","conditions":"Gastric Cancer","enrollment":180},{"nctId":"NCT03001726","phase":"","title":"To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2017-01","conditions":"Gastric Cancer","enrollment":228},{"nctId":"NCT05311189","phase":"PHASE2","title":"Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-04-15","conditions":"HER2-positive Gastric Cancer","enrollment":40},{"nctId":"NCT03961867","phase":"PHASE3","title":"Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2020-09-15","conditions":"Gastric Cancer","enrollment":440},{"nctId":"NCT04886193","phase":"NA","title":"FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Guangdong Provincial Hospital of Traditional Chinese Medicine","startDate":"2021-04-16","conditions":"Chemotherapy, Gastric Cancer","enrollment":20},{"nctId":"NCT02128243","phase":"PHASE2","title":"Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2014-09","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction, Gastric Neoplasm, Gastroesophageal Junction Adenocarcinoma","enrollment":242},{"nctId":"NCT01928524","phase":"PHASE1","title":"Chemotherapy for Patients With Cancer of the Stomach","status":"COMPLETED","sponsor":"Per Pfeiffer","startDate":"2013-09","conditions":"First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or","enrollment":34},{"nctId":"NCT03349827","phase":"NA","title":"HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer","status":"TERMINATED","sponsor":"Wuhan University","startDate":"2018-01-05","conditions":"Peritoneal Metastases From Gastric Cancer","enrollment":20},{"nctId":"NCT01283204","phase":"PHASE2","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03-09","conditions":"Recurrent or Metastatic Gastric Cancer","enrollment":180},{"nctId":"NCT03691454","phase":"PHASE2, PHASE3","title":"Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma.","status":"UNKNOWN","sponsor":"Peking University","startDate":"2018-06-28","conditions":"Gastric Adenocarcinoma","enrollment":258},{"nctId":"NCT03061058","phase":"PHASE3","title":"Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2013-04-01","conditions":"Stomach Neoplasms, Chemotherapy Effect, Chemotherapeutic Toxicity","enrollment":240},{"nctId":"NCT02960061","phase":"PHASE3","title":"Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2016-11","conditions":"Survival","enrollment":640},{"nctId":"NCT02623153","phase":"PHASE2","title":"Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer","status":"UNKNOWN","sponsor":"Tianshu Liu","startDate":"2016-01","conditions":"Gastric Cancer","enrollment":200},{"nctId":"NCT02512380","phase":"PHASE3","title":"Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2015-07","conditions":"Gastric Adenocarcinoma","enrollment":380},{"nctId":"NCT00816543","phase":"PHASE2","title":"Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-12","conditions":"Gastric Cancer","enrollment":41},{"nctId":"NCT00525005","phase":"PHASE2","title":"Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2007-08","conditions":"Stomach Neoplasms","enrollment":44},{"nctId":"NCT00587145","phase":"PHASE2","title":"Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2006-05","conditions":"Stomach Neoplasms","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Docetaxel;oxaliplatin;s1","genericName":"Docetaxel;oxaliplatin;s1","companyName":"Chinese Academy of Medical Sciences","companyId":"chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen uses three chemotherapy agents—docetaxel (microtubule stabilizer), oxaliplatin (platinum crosslinker), and S-1 (fluoropyrimidine)—to attack cancer cells through multiple mechanisms simultaneously. Used for Advanced or metastatic gastric cancer, Esophageal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}